Pharmaceuticals
credit of the month
Unattractive valuations and the overshadowing presence of patent pitfalls and litigation risk have combined to make the pharmaceutical sector one of the most interesting movers over the past few months.
Recently,Wyeth (WYE) was able to attract enough interest in a bond transaction to upsize the issue to $3 billion from $2.5 billion. Also, Schering-Plough (SPG) tapped the market for $2.4 billion in spite of ongoing legal issues and loss of patent protection on its Claritin product.
Just a month
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe
You are currently unable to print this content. Please contact info@risk.net to find out more.
You are currently unable to copy this content. Please contact info@risk.net to find out more.
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@risk.net
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@risk.net
More on Structured products
Regulation
Leaked EC clearing proposal leaves question mark over LCH
UK CCPs expected to secure equivalence, but “vague” active accounts mandate sparks fears
Receive this by email